Therapeutic drug monitoring (TDM) is the clinical practice of measuring drug concentrations. TDM can be used to determine treatment efficacy and to prevent the occurrence or reduce the risk of drug-induced side effects, being, thus, a tool of personalized medicine. Drugs for which TDM is applied should have a narrow therapeutic range and exhibit both significant pharmacokinetic variability and a predefined target concentration range. The aim of our study was to assess the current status of TDM in Greek public hospitals and estimate its progress over the last 20 years. All Greek public hospitals were contacted to provide data and details on the clinical uptake of TDM in Greece for the years 2003 and 2021 through a structured questionnaire. Data from 113 out of 132 Greek hospitals were collected in 2003, whereas for 2021, we have collected data from 98 out of 122 hospitals. Among these, in 2003 and 2021, 64 and 51 hospitals, respectively, performed TDM. Antiepileptics and antibiotics were the most common drug categories monitored in both years. The total number of drug measurement assays decreased from 2003 to 2021 (153,313 ± 7794 vs. 90,065 ± 5698; = 0.043). In direct comparisons between hospitals where TDM was performed both in 2003 and 2021 (n = 35), the mean number of measurements was found to decrease for most drugs, including carbamazepine (198.8 ± 46.6 vs. 46.6 ± 10.1, < 0.001), phenytoin (253.6 ± 59 vs. 120 ± 34.3; = 0.001), amikacin (147.3 ± 65.2 vs. 91.1 ± 71.4; = 0.033), digoxin (783.2 ± 226.70 vs. 165.9 ± 28.9; < 0.001), and theophylline (71.5 ± 28.7 vs. 11.9 ± 6.4; = 0.004). Only for vancomycin, a significant increase in measurements was recorded (206.1 ± 96.1 vs. 789.1 ± 282.8; = 0.012). In conclusion, our findings show that TDM clinical implementation is losing ground in Greek hospitals. Efforts and initiatives to reverse this trend are urgently needed.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10535589PMC
http://dx.doi.org/10.3390/pharmaceutics15092181DOI Listing

Publication Analysis

Top Keywords

2003 2021
24
public hospitals
12
tdm
10
therapeutic drug
8
drug monitoring
8
monitoring tdm
8
hospitals
8
tdm clinical
8
greek public
8
greek hospitals
8

Similar Publications

Pelvic organ prolapse (POP) is a benign condition that can adversely affect women's quality of life. Mesh sacrocolpopexy is an effective surgical treatment for POP, but is considered a complex and risky surgery for obese and elderly women. The objective of this study was to assess the impact of age and obesity on the outcomes of minimally invasive sacrocolpopexy.

View Article and Find Full Text PDF

Background: There is a shortage of patients with hypertrophic cardiomyopathy (HCM) with concurrent coronary artery disease (CAD), and the influence of CAD on the prognosis of patients with HCM is uncertain. This real-world cohort study was conducted to evaluate the prognosis of patients with patients with CAD.

Methods: This cohort study of patients with HCM was conducted from May 2003 to September 2021.

View Article and Find Full Text PDF

This study assessed effectiveness of regulations reducing environmental butyltin concentrations in Southern Chesapeake Bay over the 1999-2021 period. Water column monitoring of the Elizabeth River from 1999 to 2006 demonstrated decreasing TBT from 2003 to 2006 (average >1 ng/L at most stations) to <1 ng L by 2019 but with higher concentrations of degradation products DBT and MBT. TBT degrades to DBT and MBT within sediments, and releases degradation products over time.

View Article and Find Full Text PDF

Background: The aim is to develop age-specific anti-Müllerian hormone screening criteria for polycystic ovary syndrome to facilitate the early detection and diagnosis of the condition, and to subsequently evaluate the screening criteria.

Methods: A retrospective analysis was performed on patient data from Hangzhou Women's Hospital between July 2021 and August 2024. The use of restricted cubic spline analysis helped identify age-related inflection points, which were crucial for segmenting the patient population.

View Article and Find Full Text PDF

Pricing for Multi-Indication Drugs in the Italian Regulatory Context.

Pharmacoecon Open

January 2025

HTA & Pharmaceutical Economics Department, Italian Medicines Agency (AIFA), Rome, Italy.

Background: The authorization of new therapeutic indications for drugs already reimbursed by the Italian National Health Service (NHS) represents a matter of importance. This study aims to estimate the additional discount attributed to the extension of indications (EoIs) to explore the potential correlation between spending and negotiated discounts and to find specific factors (determinants) that impact on discount.

Methods: The study focused on drugs approved in Italy between 2003 and 2017 with at least four therapeutic indications, including the first approved and EoIs, with follow-up extended until 2021 to acquire all the information on the negotiation process that has been completed.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!